MAM
CORT icon

Meeder Asset Management’s Corcept Therapeutics CORT Stock Holding History

Meeder Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44K Buy
+28
New +$1.69K ﹤0.01% 908
2026
Q1 		– Sell
-32
Closed -$1.11K – 918
2025
Q4 		$1.11K Sell
32
-2
-6% -$157 ﹤0.01% 877
2025
Q3 		$2.83K Buy
34
+7
+26% +$507 ﹤0.01% 757
2025
Q2 		$1.98K Sell
27
-19
-41% -$1.38K ﹤0.01% 813
2025
Q1 		$5.25K Buy
+46
New +$2.8K ﹤0.01% 756
2022
Q4 		– Sell
-62
Closed -$2K – 1035
2022
Q3 		$2K Sell
62
-26
-30% -$696 ﹤0.01% 1802
2022
Q2 		$2K Sell
88
-40
-31% -$871 ﹤0.01% 1873
2022
Q1 		$3K Buy
+128
New +$2.72K ﹤0.01% 1928
2021
Q4 		– Sell
-47
Closed -$1K – 1409
2021
Q3 		$1K Sell
47
-68
-59% -$1.42K ﹤0.01% 2296
2021
Q2 		$3K Buy
115
+12
+12% +$267 ﹤0.01% 2086
2021
Q1 		$2K Buy
103
+84
+442% +$2.24K ﹤0.01% 2060
2020
Q4 		$0 Sell
19
-9,167
-100% -$193K ﹤0.01% 1942
2020
Q3 		$159K Buy
9,186
+9,171
+61,140% +$146K 0.01% 661
2020
Q2 		$0 Buy
+15
New +$211 ﹤0.01% 2119
2019
Q1 		– Sell
-610
Closed -$8K – 1725
2018
Q4 		$8K Buy
610
+143
+31% +$1.89K ﹤0.01% 1298
2018
Q3 		$7K Sell
467
-996
-68% -$13.9K ﹤0.01% 1241
2018
Q2 		$23K Sell
1,463
-524
-26% -$9.12K ﹤0.01% 933
2018
Q1 		$33K Sell
1,987
-424
-18% -$7.86K ﹤0.01% 763
2017
Q4 		$43K Buy
2,411
+1,525
+172% +$27.6K ﹤0.01% 726
2017
Q3 		$17K Buy
886
+719
+431% +$10.7K ﹤0.01% 936
2017
Q2 		$2K Buy
167
+30
+22% +$326 ﹤0.01% 1390
2017
Q1 		$2K Buy
+137
New +$1.2K ﹤0.01% 1355

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's CORT Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 28 shares worth $2.44K. The stake represents ﹤0.01% of the portfolio and ranks #908 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in CORT as recently as Q4 2025.

Meeder Asset Management first reported a position in CORT in Q1 2017 and has held it in 22 quarters since. The position peaked at $159K in Q3 2020. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Meeder Asset Management held 28 shares of Corcept Therapeutics worth $2.44K as of Q2 2026.
  • Corcept Therapeutics was a new Meeder Asset Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #908 holding.
  • Meeder Asset Management first reported a position in Corcept Therapeutics in Q1 2017 and has held it in 22 quarters since.
  • Meeder Asset Management's Corcept Therapeutics position peaked at $159K in Q3 2020.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.